World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

ADC process and analytical development at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

41 organizations at World ADC San Diego 2026 present work in process & analytical development: 27 technology and service providers, 13 drug developers and 1 academic, government or non-profit body. Between them they bring 80 presentations to the program. Most represented: Merck & Co. (6 on the program), Callio Therapeutics (4 on the program), Exelixis (4 on the program). As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–9 of 41 organizations

Organization	World ADC San Diego 2026 Attendance
Merck & Co. Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, with marketed cancer medicines and an ADC pipeline.	Panel Mon Oct 12 12:00pm Breaking Down Strategic Approaches to Ensure Product Quality in Late-Stage ADC Manufacturing Pre-conference: 8th CMC Day Talk Wed Oct 14 11:00am Harnessing Computational & Mechanistic Insights Into Chemoselective Reduction for Engineered Cysteine Site-Specific ADCs Discovery Chemistry Talk Wed Oct 14 12:00pm Assessing Case Study Characterization & Control of an ADC Variant to Mitigate Analytical Comparability Risk Process & Analytical Development Talk Wed Oct 14 2:00pm Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design Translational Medicine Talk Wed Oct 14 3:00pm Evaluating Environmental Temperature as a Hidden Critical Factor in icIEF for a Late-Stage ADC Process & Analytical Development
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Talk Tue Oct 13 12:00pm From Complexity to Manufacturability: Considerations to Rapidly Develop & Manufacture Dual Payload ADCs Manufacturing & Supply Chain Talk Tue Oct 13 2:00pm Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Exelixis, Genentech, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Chair Enhancing ADC Quality Characterization & Process Control to Rapidly & Confidently Produce Complex Conjugates Process & Analytical Development Talk Wed Oct 14 12:00pm Leveraging a Modular & Adaptable Linker Design to Evaluate Translation of Rationally Selected Dual Payload Combinations Preclinical
Exelixis Alameda, CA
exelixis.com Biotech Oncology company with marketed cabozantinib and a pipeline of biotherapeutics, including masked ADCs.	Chair Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale Pre-conference: 8th CMC Day Panel Mon Oct 12 10:30am Discussing Best Practices & Opportunities With Existing ADC Regulatory CMC Legislation & Data Submissions Pre-conference: 8th CMC Day Talk Mon Oct 12 10:30am Evaluating Design & Preclinical Characterization of XB404, a Masked ADC Targeting ROR1 & ROR2 Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 2:00pm Navigating Platform Process Development Approaches to Ensure mAb Readiness for Diverse Conjugation Approaches Process & Analytical Development Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Genentech, Callio Therapeutics, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Talk Wed Oct 14 12:00pm Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC Discovery Biology
Regeneron Tarrytown, NY
regeneron.com Large pharma Develops and markets antibody medicines, and researches new linker-payloads and bioconjugate designs beyond classic cytotoxic ADCs.	Chair Pushing the Boundary of Novel Bioconjugate Mechanisms & Design Pre-conference: 4th Novel Conjugates Day Talk Mon Oct 12 12:00pm Spotlighting Discovery of Novel Linker Payloads to Set the Path for the Next Wave of Differentiated Antibody Conjugates Pre-conference: 4th Novel Conjugates Day Panel Mon Oct 12 3:00pm Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation Pre-conference: 4th Novel Conjugates Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Wed Oct 14 12:00pm The 18-Month Journey to Clinic for ADCs: How Operational Strategy Sets The Pace for IND Manufacturing & Supply Chain Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Bristol Myers Squibb, Gilead Sciences
AbbVie North Chicago, IL
abbvie.com Large pharma Global pharmaceutical company developing antibody-drug conjugates in oncology, including ABBV-400 for colorectal and other solid tumors.	Talk Mon Oct 12 2:00pm Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs Pre-conference: 3rd Pharmacology Day · with MediLink Therapeutics Panel Mon Oct 12 2:30pm Breaking Down Learnings From Pharmacology & PD Profiles to Understand In-Depth Insights for the Next Wave of ADCs Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 12:00pm Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need Clinical Lessons Talk Wed Oct 14 9:00am Delving Into Discovery of Pan-PI3K & mTOR Dual Inhibitors as a First-in-Class ADC Payload Plenary ADC discovery chemistry Talk Wed Oct 14 2:30pm Investigating Best Technologies & Methods to Scale Up Process From Lab to GMP Across ADC Formats Process & Analytical Development
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company with oncology, immunology and cardiovascular medicines and a pipeline that includes bispecific ADCs.	Talk Mon Oct 12 2:30pm ADC Photosensitivity: Detailing Methodologies to Adapt Manufacturing & Site Requirements to Combat Payload-Specific Photodegradation Pre-conference: 8th CMC Day Talk Mon Oct 12 2:30pm Understanding ADC Charge Variants to Enable Effective CQA Assessment & Control Strategy Pre-conference: 2nd Analytical & CQA Day Talk Tue Oct 13 11:00am Showcasing Capability & Application of Automated HLPC to Undergo ADC Process Development Optimization Process & Analytical Development Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Regeneron, Gilead Sciences
Eli Lilly Indianapolis, IN
lilly.com Large pharma Global pharmaceutical company with an oncology pipeline that includes antibody-drug conjugates.	Chair Elevating Confident Characterization of Increasingly Complex Conjugates Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:00am Laying Out ADC CQAs & Understanding Regulatory Quality Perspectives as Complex Biologic & Small Molecule Therapies Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:30am Exploring Sofetabart Mipitecan Enhanced Anti-Tumor Activity in Combination with SoC Therapies in Ovarian Cancer Models to Support Clinical Development Pre-conference: 10th ADCs in Combination Day Workshop Thu Oct 15 9:00am Deep Diving Into CMC Best Practices to Ensure Stakeholder Alliance to Optimize ADC Production & Regulatory CMC Strategy Post-conference workshop for Manufacturing & Supply Chain · with Amgen
Gilead Sciences Foster City, CA
gilead.com Large pharma Biopharmaceutical company with marketed HIV, liver disease and cancer medicines, including the TROP2 ADC sacituzumab govitecan.	Talk Tue Oct 13 6:15pm TROP2 ADC–Immunotherapy Combinations: Clinical Evidence, Emerging Strategies & Future Opportunities Plenary Clinical development Talk Wed Oct 14 5:00pm Highlighting the Clinical Promise from Phase I/IIa Development of TUB-040 in Platinum Resistant Ovarian Cancer Plenary Clinical development Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Regeneron, Bristol Myers Squibb
Takeda Tokyo, Japan
takeda.com Large pharma Japanese pharmaceutical company with marketed medicines in oncology, rare diseases, gastroenterology and other areas.	Talk Tue Oct 13 2:00pm Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines Manufacturing & Supply Chain Talk Wed Oct 14 2:00pm Developing an On-Column Capping Approach to Reduce Charge Heterogeneity of THIOMAB ADCs Process & Analytical Development Talk Wed Oct 14 2:30pm Beyond Allometry: Assessing Translational PK/PD Modeling for Human Projection of a Nonlinear Immune Cell Directed ADC Translational Medicine